Somatostatin, substance P, vasoactive intestinal polypeptide, and neuropeptide Y receptors: critical assessment of biochemical methodology and results.
Undén
A
A
Peterson
L L
LL
Bartfai
T
T
D000067956:Adenylyl Cyclase Inhibitors; D000262:Adenylyl Cyclases / Q000378:metabolism; D000327:Adsorption; D000595:Amino Acid Sequence; D000818:Animals; D001681:Biological Assay; D001921:Brain / Q000378:metabolism; D002352:Carrier Proteins / Q000378:metabolism; D004355:Drug Stability; D006801:Humans; D006863:Hydrogen-Ion Concentration; D007700:Kinetics; D009419:Nerve Tissue Proteins / Q000378:metabolism* / Q000494:pharmacology; D009478:Neuropeptide Y; D011487:Protein Conformation; D011869:Radioligand Assay / Q000379:methods*; D011956:Receptors, Cell Surface / Q000032:analysis* / Q000145:classification / Q000187:drug effects; D013004:Somatostatin / Q000378:metabolism / Q000494:pharmacology; D013373:Substance P / Q000378:metabolism / Q000494:pharmacology; D014660:Vasoactive Intestinal Peptide / Q000378:metabolism / Q000494:pharmacology
D000067956:Adenylyl Cyclase Inhibitors; D002352:Carrier Proteins; D009419:Nerve Tissue Proteins; D009478:Neuropeptide Y; D011956:Receptors, Cell Surface; D013373:Substance P; D014660:Vasoactive Intestinal Peptide; D013004:Somatostatin; D000262:Adenylyl Cyclases